DexCom, Inc. (NASDAQ:DXCM) Shares Sold by Headlands Technologies LLC

Headlands Technologies LLC reduced its holdings in shares of DexCom, Inc. (NASDAQ:DXCM - Free Report) by 58.0% in the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 6,248 shares of the medical device company's stock after selling 8,620 shares during the quarter. Headlands Technologies LLC's holdings in DexCom were worth $486,000 at the end of the most recent quarter.

Several other large investors also recently made changes to their positions in DXCM. Geode Capital Management LLC raised its position in DexCom by 0.6% in the fourth quarter. Geode Capital Management LLC now owns 9,993,698 shares of the medical device company's stock valued at $775,256,000 after purchasing an additional 56,094 shares during the period. Tradewinds LLC. acquired a new stake in shares of DexCom in the fourth quarter valued at about $278,000. HighPoint Advisor Group LLC purchased a new stake in shares of DexCom during the 4th quarter valued at about $427,000. Alliancebernstein L.P. lifted its position in DexCom by 24.1% during the 4th quarter. Alliancebernstein L.P. now owns 555,164 shares of the medical device company's stock worth $43,175,000 after acquiring an additional 107,916 shares in the last quarter. Finally, O Shaughnessy Asset Management LLC boosted its holdings in DexCom by 16.9% in the 4th quarter. O Shaughnessy Asset Management LLC now owns 13,384 shares of the medical device company's stock worth $1,041,000 after acquiring an additional 1,930 shares during the period. Institutional investors and hedge funds own 97.75% of the company's stock.

Analyst Ratings Changes

A number of analysts have recently issued reports on DXCM shares. Wells Fargo & Company reiterated an "overweight" rating on shares of DexCom in a research note on Saturday, March 8th. Morgan Stanley boosted their price objective on shares of DexCom from $75.00 to $82.00 and gave the stock an "equal weight" rating in a report on Friday, February 14th. Baird R W upgraded DexCom from a "hold" rating to a "strong-buy" rating in a research note on Thursday, January 16th. Redburn Atlantic upgraded DexCom from a "neutral" rating to a "buy" rating and boosted their price target for the stock from $85.00 to $115.00 in a research note on Monday, February 3rd. Finally, Citigroup increased their price target on DexCom from $101.00 to $104.00 and gave the company a "buy" rating in a report on Tuesday, March 4th. Five analysts have rated the stock with a hold rating, thirteen have given a buy rating and two have given a strong buy rating to the company. Based on data from MarketBeat, the stock has an average rating of "Moderate Buy" and a consensus price target of $99.82.

Remove Ads

DexCom Stock Performance

Shares of NASDAQ:DXCM traded up $6.15 during trading on Wednesday, reaching $66.84. 6,696,624 shares of the company's stock traded hands, compared to its average volume of 4,149,361. The stock has a market capitalization of $26.21 billion, a P/E ratio of 46.74, a price-to-earnings-growth ratio of 2.30 and a beta of 1.50. DexCom, Inc. has a 12 month low of $57.52 and a 12 month high of $141.25. The company has a 50 day moving average of $77.74 and a 200-day moving average of $76.63. The company has a debt-to-equity ratio of 0.59, a current ratio of 1.47 and a quick ratio of 1.28.

DexCom (NASDAQ:DXCM - Get Free Report) last posted its earnings results on Thursday, February 13th. The medical device company reported $0.45 EPS for the quarter, missing the consensus estimate of $0.50 by ($0.05). DexCom had a net margin of 14.29% and a return on equity of 30.14%. On average, equities analysts expect that DexCom, Inc. will post 2.03 EPS for the current year.

Insider Transactions at DexCom

In other DexCom news, COO Jacob Steven Leach sold 14,076 shares of DexCom stock in a transaction on Wednesday, March 12th. The stock was sold at an average price of $70.38, for a total transaction of $990,668.88. Following the sale, the chief operating officer now owns 313,497 shares of the company's stock, valued at $22,063,918.86. The trade was a 4.30 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, EVP Jereme M. Sylvain sold 2,090 shares of DexCom stock in a transaction dated Wednesday, January 29th. The shares were sold at an average price of $86.91, for a total transaction of $181,641.90. Following the sale, the executive vice president now owns 83,526 shares in the company, valued at approximately $7,259,244.66. This represents a 2.44 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders sold 105,009 shares of company stock worth $8,044,178. Insiders own 0.30% of the company's stock.

About DexCom

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.